Cannabinoid‐mediated neuroprotection following interferon‐gamma treatment in a three‐dimensional mouse brain aggregate cell culture

Multiple sclerosis is increasingly recognized as a neurodegenerative disease which is triggered by inflammation in the central nervous system (CNS). Demyelination‐associated axonal or neuronal damage is a primary cause of disability and has thus far not been successfully targeted by available drug therapies. The neuroprotective properties of both endogenous and administered cannabinoids have been shown in in vivo and in vitro models of CNS damage following excitotoxic, oxidative, traumatic and ischaemic insults, with a predominantly apoptotic effector mechanism. In this study a foetal mouse telencephalon aggregate cell culture system was developed to compare tissue from cannabinoid receptor 1 knockout mice with wildtype counterparts. Aggregate formation and neurofilament/myelin basic protein accumulation were dependent on the age of foetal dissection and species used. Following treatment with interferon‐γ, levels of myelin basic protein, neurofilament, neuronal dephosphorylation and caspase 3 activation were assessed in telencephalon tissue in vitro. Cytokine treatment resulted in significant loss of the neuronal marker neurofilament‐H in cannabinoid receptor 1 knockout cultures but not in wildtypes, indicating that presence of the cannabinoid receptor 1 gene can be neuroprotective. Caspase 3 activation was higher in cultures from knockout animals, indicating an apoptotic mechanism of cell death. Dephosphorylated neurofilament levels were significantly elevated in knockout mice, lending support to the premise that neurofilament dephosphorylation is a marker for neuronal damage. Taken together, these results indicate that neuroprotection could be elicited through the cannabinoid receptor 1, and point towards a potential therapeutic role for cannabinoid compounds in demyelinating conditions such as multiple sclerosis.

[1]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[2]  M. Ameloot,et al.  Cytokine‐induced cell death in human oligodendroglial cell lines. II: Alterations in gene expression induced by interferon‐γ and tumor necrosis factor‐α , 2004, Journal of neuroscience research.

[3]  M. Cuzner,et al.  Remyelination of cytokine‐ or antibody‐demyelinated CNS aggregate cultures is inhibited by macrophage supplementation , 2004, Glia.

[4]  A. Izzo,et al.  Neuroprotective effect of cannabidiol, a non‐psychoactive component from Cannabis sativa, on β‐amyloid‐induced toxicity in PC12 cells , 2004, Journal of neurochemistry.

[5]  J. Zajicek,et al.  Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial , 2003, The Lancet.

[6]  K. Schulze-Osthoff,et al.  Non-apoptotic functions of caspases in cellular proliferation and differentiation. , 2003, Biochemical pharmacology.

[7]  M. Eder,et al.  CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.

[8]  A. Thompson,et al.  Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. , 2003, Brain : a journal of neurology.

[9]  Richard Reynolds,et al.  NG2-expressing glial progenitor cells: an abundant and widespread population of cycling cells in the adult rat CNS , 2003, Molecular and Cellular Neuroscience.

[10]  H. Hartung,et al.  Multiple paradigm shifts in multiple sclerosis. , 2003, Current opinion in neurology.

[11]  F. Walsh,et al.  The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response , 2003, The Journal of cell biology.

[12]  D. Wade,et al.  A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms , 2003, Clinical rehabilitation.

[13]  K. Jin,et al.  Increased Severity of Stroke in CB1 Cannabinoid Receptor Knock-Out Mice , 2002, The Journal of Neuroscience.

[14]  J. Sullivan,et al.  Cannabinoid receptors , 2002, Current Biology.

[15]  J. W. Brooks,et al.  Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. , 2002, European journal of pharmacology.

[16]  Beat Lutz,et al.  Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1 , 2002, Journal of neurochemistry.

[17]  S. Ben-Shabat,et al.  An endogenous cannabinoid (2-AG) is neuroprotective after brain injury , 2001, Nature.

[18]  Guy C. Brown,et al.  Inflammatory Neurodegeneration Mediated by Nitric Oxide from Activated Glia-Inhibiting Neuronal Respiration, Causing Glutamate Release and Excitotoxicity , 2001, The Journal of Neuroscience.

[19]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.

[20]  S. McAllister,et al.  Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity , 2001, Neuroscience Letters.

[21]  M. Grimaldi,et al.  Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity , 2001, The European journal of neuroscience.

[22]  Kenneth J. Smith,et al.  Electrically active axons degenerate when exposed to nitric oxide , 2001, Annals of neurology.

[23]  A. Rivett,et al.  Regulation of proteasome complexes by γ-interferon and phosphorylation , 2001 .

[24]  H. Pant,et al.  Neurofilament protein synthesis and phosphorylation , 2000, Journal of neurocytology.

[25]  M. Cuzner,et al.  Temporal analysis of growth factor mRNA expression in myelinating rat brain aggregate cultures: Increments in CNTF, FGF‐2, IGF‐I, and PDGF‐AA mRNA are induced by antibody‐mediated demyelination , 2000, Glia.

[26]  Shuxian Hu,et al.  Cytokine Effects on Glutamate Uptake by Human Astrocytes , 2000, Neuroimmunomodulation.

[27]  R. Pertwee,et al.  Cannabinoids control spasticity and tremor in a multiple sclerosis model , 2000, Nature.

[28]  D. Linden,et al.  Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells. , 2000, Journal of neurophysiology.

[29]  B. Popko,et al.  Major histocompatibility complex heavy chain accumulation in the endoplasmic reticulum of oligodendrocytes results in myelin abnormalities , 2000, Journal of neuroscience research.

[30]  A. Ishida-Yamamoto,et al.  Fas antigen modulates ultraviolet B-induced apoptosis of SVHK cells: sequential activation of caspases 8, 3, and 1 in the apoptotic process. , 1999, Experimental cell research.

[31]  K. Jin,et al.  Cannabinoids and Neuroprotection in Global and Focal Cerebral Ischemia and in Neuronal Cultures , 1999, The Journal of Neuroscience.

[32]  M. Parmentier,et al.  Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. , 1999, Science.

[33]  H. Pahl,et al.  The ER-overload response: activation of NF-κB , 1997 .

[34]  V. del Pozo,et al.  Modulation of the Fc gamma RII and Fc gamma RIII induced by GM-CSF, IFN-gamma and IL-4 on murine eosinophils. , 1994, Immunology.

[35]  M. Cuzner,et al.  Myelin basic protein content of aggregating rat brain cell cultures treated with cytokines and/or demyelinating antibody: Effects of macrophage enrichment , 1994, Journal of neuroscience research.

[36]  L. Ignarro,et al.  Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. , 1993, Journal of immunology.

[37]  C. Brosnan,et al.  Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. , 1991, Journal of immunology.

[38]  D. Linch,et al.  FcγRII‐Mediated Superoxide Production by Phagocytes Is Augmented by GM‐CSF Without a Change in FCγRII Expression , 1990 .

[39]  B. Uitdehaag,et al.  Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon‐gamma in Lewis rats , 1990, Clinical and experimental immunology.

[40]  A. Billiau,et al.  Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. , 1988, Journal of immunology.

[41]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[42]  D. Silberberg,et al.  The expression of MHC antigens on oligodendrocytes: Induction of polymorphic H-2 expression by lymphokines , 1986, Journal of Neuroimmunology.

[43]  L. Sternberger,et al.  Monoclonal antibodies distinguish phosphorylated and nonphosphorylated forms of neurofilaments in situ. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[45]  A. Rivett,et al.  Regulation of proteasome complexes by gamma-interferon and phosphorylation. , 2001, Biochimie.

[46]  H. Pahl,et al.  The ER-overload response: activation of NF-kappa B. , 1997, Trends in biochemical sciences.

[47]  D. Linch,et al.  Fc gamma RII-mediated superoxide production by phagocytes is augmented by GM-CSF without a change in Fc gamma RII expression. , 1990, Journal of leukocyte biology.

[48]  Paul Honegger,et al.  Biochemical Differentiation in Serum-Free Aggregating Brain Cell Cultures , 1985 .